The Anti-Osteoporosis Therapy and Fracture Healing Market Size was valued at USD 33.52 billion in 2022. It is projected to reach USD 69.28 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2023-2031).
Osteoporosis is a common condition that makes the bones abnormally thin, fragile, and brittle. Due to lower levels of estrogen, a female hormone that aids in maintaining bone mass, women are more susceptible to osteoporosis after menopause. Smoking, certain medications, including steroids, proton pump inhibitors, and some combination therapy, malnutrition, and certain diseases, such as rheumatoid arthritis (RA) and multiple myeloma, are additional risk factors for osteoporosis. Generally, the spine, hip, shoulder, and forearm are affected by the disease. Most hip fractures result in mobility loss and long-term nursing care for almost one-third of patients. Long-term complications resulting from bed immobilization can undoubtedly result in fatality. X-ray and radiography tests, as well as bone density tests, are among the osteoporosis diagnostic tools.
| Report Metric | Details |
|---|---|
| Base Year | 2022 |
| Study Period | 2021-2031 |
| Forecast Period | 2023-2031 |
| CAGR | 8.4% |
| Market Size | 69.28 |
| Fastest Growing Market | Europe |
| Largest Market | North America |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
| Geographies Covered |
|
In older women and men, osteoporosis is a severe clinical problem. Due to osteoporosis' increased bone fragility, almost any bone can fracture. These fractures are linked to more expensive medical care, physical impairment, decreased quality of life, and higher mortality. Measures to diagnose and prevent osteoporosis and its complications have become a significant public health concern because the incidence of osteoporotic fracture rises with advancing age. Approximately 44 million Americans have low bone density, which puts them at higher risk, and another 10 million have osteoporosis. Half of all adults in America over the age of 50 are at risk of osteoporosis. Thus the rising prevalence of osteoporosis in the geriatric population will contribute to the growth of the anti-osteoporosis therapy and fracture healing market over the forecast period.
Lifestyle changes in the 21st century and unhealthy eating habits have drastically increased bone diseases worldwide. A diet lacking calcium increases the risk of fractures, early bone loss, and diminished bone density. Physically inactive people are more likely to develop osteoporosis than physically active people. According to research, smoking can cause brittle bones. The risk of osteoporosis may also be increased by consuming more than one alcoholic drink per day for women or two alcoholic drinks per day for men. Thus, the risk of diseases like osteoporosis increases, propelling market growth over the forecast period.
The anti-osteoporosis therapy has few side effects that can cause harm to the older patient, and it has a low success rate for complete treatment. Despite having access to effective, secure, and affordable treatment, many women who are at high risk for fractures opt not to start treatment, and 50% of those women stop the treatment within a year. Limited use of bisphosphonates, whether due to low initiation rates, low adherence rates, or high discontinuation rates, fails to reduce the risk of osteoporotic fractures, which can raise healthcare costs and significantly decrease quality of life and life expectancy. Moreover, the inconvenience related to medication also reduces the use of bisphosphonates in long-term treatment.
Innovations in osteoporosis treatment and the development of new drugs with minimal side effects are expected to increase the growth rate of the anti-osteoporosis therapy and fracture healing market. Purdue University innovators developed a new form of a drug used to treat osteoporosis that comes with fewer side effects and may provide a new option for patients.
The peptide drug-human calcitonin, which is already used to treat osteoporosis in patients, has been stabilized by researchers. Scientists turned it into a prodrug to improve the peptide hormone's ability to treat osteoporosis. Similarly, a new treatment called 'Romosozumab' helps in the new bone building to treat osteoporosis, in which injection is given every month and is limited to one year of treatment.
The global anti-osteoporosis therapy and fracture healing market share is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant shareholder in the global anti-osteoporosis therapy and fracture healing market and is expected to grow at a healthy CAGR during the forecast period. The larger share is due to increased spending on research and development to create new medications, an aging population, and increased diseases brought on by changing lifestyles. To treat osteoporosis in postmenopausal women who are at a high risk of breaking a bone, the U.S. Food and Drug Administration approved Evenity (romosozumab) on April 2019. Evenity is a monoclonal antibody that works primarily by promoting the formation of new bone and blocks the effects of the protein sclerostin. One monthly injection of Evenity is administered by a medical professional and consists of two injections, one right after the other.
Europe is expected to grow at a healthy CAGR during the forecast period. The high prevalence of osteoporosis due to physical inactivity and the rising obese population will likely support the market growth. Changing eating habits and poor nutrition lead to calcium deficiency and different bone diseases, which in turn is likely to fuel the market growth. In Europe, osteoporosis is a significant and growing healthcare issue that contributes to more than 4.3 million fragility fractures each year, with enormous healthcare expenditures. However, it continues to be gravely underdiagnosed and undertreated, with an estimated 71% of European women at high risk for the condition not receiving preventative care. Thus, growing awareness about anti-osteoporosis therapy and fracture healing will help in the growth of the market worldwide over the forecast period.
The Asia-Pacific region is also growing at a substantial CAGR. In China, osteoporosis is estimated to impact 49.3 million women and 10.9 million men, with increasing cases every year due to changing lifestyles. Every year in India, around 10 million people experience fractures due to osteoporosis, and the high prevalence of back pain in women after menopause is likely to support the market growth. Furthermore, growing incidences of calcium deficiency in Japan are propelling the market growth.
LAMEA region is projected to contribute to the growth of the anti-osteoporosis therapy and fracture healing market. The UAE has one of the highest rates of vitamin D deficiency in the world, leading to an increased risk of osteoporosis in the region. Factors such as a sedentary lifestyle and unhealthy diet also increase osteoporosis cases. According to hospital-based studies, there were between 40 and 362 hip fractures per 100,000 people aged above 50 in Colombia, Chile, Brazil, Mexico, Panama, Peru, and Venezuela.
The global anti-osteoporosis therapy and fracture healing market are segmented by route of administration and drug type.
Based on route of administration, the global anti-osteoporosis therapy and fracture healing market are bifurcated into oral and injectable.
The oral segment is the highest contributor to the market and is expected to grow at a healthy CAGR during the forecast period. The larger share is linked to the convenience factor involved with oral drugs and the availability of oral drugs in several regions. The oral drugs are more cost-effective and do not require nursing staff for treatment, as required in injectable treatment. The growing adoption of bisphosphonates for the treatment of osteoporosis is contributing heavily to the growth of the oral drug segment.
Based on drug type, the global anti-osteoporosis therapy and fracture healing market are bifurcated into bisphosphonates, antibody drugs, and selective estrogen receptor modules.
The bisphosphonates segment is the highest contributor to the market and is expected to grow at a healthy CAGR during the forecast period. Bisphosphonates are the most widely used drugs to treat osteoporosis. They are frequently the first therapies suggested for postmenopausal women. The types of bisphosphonates include Alendronate (Fosamax), an oral medication people take daily or once per week, and ibandronate (Boniva), a monthly oral tablet or an intravenous injection you receive four times a year. Risedronate (Actonel), a daily, weekly, or monthly dose in an oral tablet, and zoledronic acid (Reclast). This intravenous infusion can be received once every one to two years by the patient.
The global anti-osteoporosis therapy and fracture healing market’s major key players are
